Autoinjectors for Injectable Drugs Positioned to Overtake Pen Injectors by 2018

Share Article

Lower cost disposable injectors key to growth according to a New Analysis of Prefilled Device Markets by Applied Data Analytics

As the number of injectable drugs designed to be self-administered has grown in recent years, specialty injection devices – specifically autoinjectors and pen injectors – have experienced healthy unit growth. These devices are gaining market penetration by improving patient compliance and safety, and by providing drug marketers with a path to differentiate their drug products in the age of Direct-to-Consumer marketing.

Autoinjectors owe their existence to the emergence of the prefilled syringe as a major drug delivery platform. For many years, autoinjectors filled a niche market, allowing patients who self-administered injectable drugs supplied in prefilled syringes to perform injections more consistently and safely. These autoinjectors, designed to be reused, were rugged and costly to manufacture.

Improvements in materials technology and device design led to the creation of autoinjectors that can be made economically in high production quantities, opening the door for the disposable autoinjector. The first disposable autoinjectors entered the market in 2010. Since then, they’ve achieved double-digit annual growth. The number of drugs available in prefilled syringes as a percentage of all injectable drugs continues to grow. The majority of these injectable drugs are indicated for chronic conditions and self-administration - factors that represent positive market dynamics for autoinjectors over the near term.

In the coming months and years, the market competition between autoinjectors and pen injectors will have important implications for market participants, patients and the healthcare ecosystem as a whole. Pen injectors are still a dominant presence in the self-administered injectables sector. Pens are firmly entrenched in two key market segments – diabetes and human Growth Hormone. This will not change as patients are comfortable with their current device.

Autoinjector growth will be particularly high in the area of new specialty injectables that formerly would have been marketed in pen injectors. This trend is already evident in the number of newer injectables that are evolving along the typical post-launch product packaging pathway from vials to prefilled devices, where autoinjectors have been gaining product wins at the expense of pens.

These findings are available in a new report, researched, written and published by Applied Data Analytics. For more information, please visit:

About Applied Data Analytics

Applied Data Analytics assists life science management decision makers by providing analysis services and products that can reveal key relationships, patterns and trends affecting their businesses. These information tools encourage opportunity and risk discovery by promoting comprehensive, timely, and insightful analysis, allowing managers to make informed tactical and strategic decisions.


Greg Stone
Voice: 603-718-4564            
Source: Applied Data Analytics

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Greg Stone
Email >
Visit website